Sigyn Therapeutics, Inc. (SIGY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 50K 100K 150K FY18: 28.3K FY19: 143.3K FY18 FY19

Gross Profit Annual

0 40K 80K 120K FY18: 18.6K FY19: 107.7K FY18 FY19

Operating Income Annual

-2.7M -1.8M -900K 0 900K 1.8M 2.7M FY23: -2.5M FY24: -2.5M FY23 FY24

Net Income Annual

-4.5M -3M -1.5M 0 1.5M 3M 4.5M FY23: -4.1M FY24: -3.3M FY23 FY24

Cost of Revenue Annual

0 15K 30K 45K FY18: 9.7K FY19: 35.7K FY18 FY19

Operating Cash Flow Annual

-1.5M -1M -500K 0 500K 1M 1.5M FY23: -1.4M FY24: -872.4K FY23 FY24

Free Cash Flow Annual

-2.1M -1.4M -700K 0 700K 1.4M 2.1M FY21: -1.8M FY22: -1.8M FY21 FY22

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 500K 1M 1.5M FY23: 1.1M FY24: 1.3M FY23 FY24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '23: -3.82 Q1 '24: -3.05 Q2 '24: -3.08 Q3 '24: -3.20 Q4 '24: -2.51 Q1 '25: -2.31 Q2 '25: -2.51 Q3 '25: -1.93 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.